Exagen Inc. AVISE Testing Now Covered and In-Network with TRICARE East
July 27 2020 - 4:05PM
Exagen Inc. (Nasdaq: XGN), an organization dedicated to
transforming the care continuum for patients suffering from
autoimmune diseases, today announced that all AVISE test offerings
(CTD, Lupus, SLE Prognostic, SLE Monitor, APS, MTX and HCQ) will be
a contracted covered service with TRICARE East managed care support
contractor Humana Military to optimize the care of these
patients. The agreement will make AVISE tests available to
approximately 6 million beneficiaries.
“We are proud to support the TRICARE East beneficiaries,
enabling rheumatologists to improve patient care through the
differential diagnosis, prognosis and monitoring of complex
autoimmune diseases, including SLE,” said Ron Rocca, President and
CEO of Exagen. “Lupus, which is two to three times more prevalent
among women of color than among Caucasian women, is an
unpredictable and misunderstood disease that ravages different
parts of the body. It is difficult to diagnose, hard to live
with, a challenge to treat, and can be fatal.”
“We are pleased to offer Exagen as an in-network provider for
TRICARE East beneficiaries,” said Brent Densford, President of
Humana Military.
About Exagen Inc.
Exagen is dedicated to transforming the care continuum for
patients suffering from debilitating and chronic autoimmune
diseases by enabling timely differential diagnosis and optimizing
therapeutic intervention. Exagen has developed and is
commercializing a portfolio of innovative testing products under
its AVISE brand, several of which are based on our proprietary
Cell-Bound Complement Activation Products, or CB-CAPs,
technology. Exagen’s goal is to enable rheumatologists to
improve care for patients through the differential diagnosis,
prognosis and monitoring of complex autoimmune and autoimmune
related diseases, including SLE and rheumatoid arthritis. For
further information please visit www.exagen.com.
About TRICARE
TRICARE is the health care program for uniformed service
members, retirees, and their families around the world.
TRICARE provides comprehensive coverage to all 9.5M beneficiaries,
including: Health plans, Special programs, Prescriptions, Dental
plans, Most TRICARE health plans meet the requirements for minimum
essential coverage under the Affordable Care Act.
TRICARE is managed by the Defense Health Agency under leadership of
the Assistant Secretary of Defense (Health Affairs). For
further information please visit
https://tricare.mil/About/Facts.
About Humana Military
Humana Military, a wholly-owned subsidiary of Humana Inc.,
partners with the Department of Defense to administer the TRICARE
health program for military members, retirees and their families in
the East Region. For more than 20 years, Humana Military has
strived to create better health outcomes and simplified experiences
for millions of beneficiaries across the United States through
TRICARE and other military healthcare programs. High-quality
service, cost-effective platforms and progressive approaches to
care drive Humana Military to be a thought leader in the industry
and an essential partner to the government.
Forward Looking Statements
Exagen cautions you that statements in this press release that
are not a description of historical facts are forward-looking
statements. These statements are based on the Company's
current beliefs and expectations. Such forward-looking statements
include, but are not limited to, statements regarding the expected
guidance from the Exagen Scientific Advisory Board, and any
potential for increased use of AVISE laboratory tests. The
inclusion of forward-looking statements should not be regarded as a
representation by Exagen that any of its plans will be achieved.
Actual results may differ from those set forth in this press
release due to the risks and uncertainties inherent in Exagen’s
business, including, without limitation: Exagen’s commercial
success depends upon attaining and maintaining significant market
acceptance of its testing products and promoted therapeutics among
rheumatologists, patients, third-party payers and others in the
medical community; risks associated with maintaining third-party
collaborations such as consulting advisors and Exagen’s performance
thereunder; and other risks described in the Company’s prior press
releases and in the Company’s filings with the Securities and
Exchange Commission, including under the heading "Risk Factors" in
the Company’s Registration Statement on Form S-1 and any subsequent
filings with the SEC. You are cautioned not to place undue
reliance on these forward-looking statements, which speak only as
of the date hereof, and we undertake no obligation to revise or
update this press release to reflect events or circumstances after
the date hereof. All forward-looking statements are qualified
in their entirety by this cautionary statement, which is made under
the safe harbor provisions of the Private Securities Litigation
Reform Act of 1995.
CONTACTS:
Investors
Westwicke Partners
Mike Cavanaugh
Mike.Cavanaugh@westwicke.com
646.677.1838
Company
Exagen Inc.
Kamal Adawi, Chief Financial Officer
KAdawi@exagen.com
760.477.5514
Exagen (NASDAQ:XGN)
Historical Stock Chart
From Mar 2024 to Apr 2024
Exagen (NASDAQ:XGN)
Historical Stock Chart
From Apr 2023 to Apr 2024